

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Global PRoMiSe (Perioperative Recommendations for Medication Safety): Protocol for a mixed-methods study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038313
Article Type:	Protocol
Date Submitted by the Author:	09-Mar-2020
Complete List of Authors:	Nanji, Karen; Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine Merry, Alan; Auckland City Hospital, Dept of Anaesthesiology Shaikh, Sofia; Massachusetts General Hospital, Pagel, Christina; University College London Deng, Hao; Massachusetts General Hospital, Department of Anesthesia Critical Care and Pain Medicine Wahr, Joyce; University of Minnesota Medical Center, Anesthesiology Gelb, Adrian; University of California San Francisco, Anesthesia and Perioperative Care Orser, Beverley; Sunnybrook Health Sciences Centre, Anesthesia
Keywords:	Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Adult anaesthesia < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Global PRoMiSe (Perioperative Recommendations for Medication Safety):

Protocol for a mixed-methods study

Nanji KC^{1, 2, 3}, Merry AF^{4, 5}, Shaikh S¹, Pagel C⁶, Deng H¹, Wahr J⁷, Gelb A⁸, and Orser BA^{9,10}.

1. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.
2. Harvard Medical School, Boston, MA, USA.
3. Partners Healthcare Systems, Inc., Wellesley, MA, USA.
4. Department of Anaesthesiology, School of Medicine, University of Auckland, Auckland, New Zealand.
5. Department of Anaesthesia, Auckland City Hospital, Auckland, New Zealand.
6. Clinical Operational Research Unit, University College London, London, UK.
7. Department of Anesthesiology, University of Minnesota, Minneapolis, MN, USA.
8. Department of Anesthesia & Perioperative Care, University of California San Francisco, San Francisco, CA, USA.
9. Department of Anesthesia, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
10. Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.

Corresponding Author:

Karen C. Nanji, MD MPH

Department of Anesthesia, Critical Care and Pain Medicine

Massachusetts General Hospital

55 Fruit Street, Boston, MA 02114

KNANJI@mgh.harvard.edu

T: 617.838.6690

Word Count: 3,839

Key Words: Anesthesia, Medication Errors, Patient Safety

ABSTRACT

Introduction: Medication errors (MEs), which occur commonly in the perioperative period, have the potential to cause patient harm or death. Many published recommendations exist for preventing perioperative MEs; however, many of these recommendations conflict and are often not applicable to middle and low income countries. The goal of this study is to develop and disseminate consensus-based recommendations for perioperative medication safety that are tailored to country income level.

Methods and Analysis: The primary site of this mixed-methods study is Massachusetts General Hospital/Harvard Medical School. Participants include 108 international medication safety experts, 27 from each of the World Bank's four country income groups (high, upper-middle, lower-middle and low income). Using the Delphi method, participants will rate the appropriateness of candidate medication safety recommendations by completing online surveys using REDCAP. We will use Condorcet ranking methods to prioritize the final recommendations for each country income group. We will execute a comprehensive dissemination strategy for the recommendations across each country income group. Finally, we will conduct semi-structured interviews with our participants to evaluate the initial adoption and implementation of the recommendations in each country income group.

Ethics and Dissemination: This study was approved by the Human Research Committee/Institutional Review Board at Partners Healthcare (2019P003567), and is registered on clinicaltrials.gov (NCT04240301). Findings will be published in peer-reviewed journals and presented at local and international conferences.

ARTICLE SUMMARY

Strengths and limitations of this study:

- Robust mixed-methods study design to include a large number of participants
- Recommendations that target the entire perioperative medication use process.
- First medication safety initiative to include equal representation from each of the World Bank's four country income groups, allowing for generalizability of recommendations internationally, regardless of country income level.
- World Federation of Societies of Anesthesiologists (WFSA) endorsed the study and deemed it to be a priority.
- While we will translate all study documents and have interpreters available in each of the World Health Organizations six official languages (Arabic, Chinese, English, French, Russian and Spanish), language barriers may impact the participation of experts who are not fluent in any of these languages.

INTRODUCTION

Perioperative medication errors (MEs) have the potential to cause serious patient harm.

Growing evidence indicates that MEs and adverse medication events (AMEs) are as common in the perioperative setting as they are in other hospital environments.^{1,2} However, medication use in the perioperative setting presents particular challenges to patient safety. The delivery of medications in the operating room usually bypasses standard safety checks, such as electronic physician order entry systems that include clinical decision support and alerts, approvals by pharmacists, and double-checks by nurses prior to medication administration. Furthermore, the high-stress, time-sensitive nature of work in the operating room can contribute to high rates of MEs and errors of greater severity in the operating room compared with other clinical settings. In the operating room, syringe swaps, ampoule swaps, and wrong dose errors can cause serious harm.³ In fact, the most frequently cited critical adverse events in anesthesia are MEs.⁴ Surprisingly, after decades of decline, the worldwide death rate during anesthesia is once again increasing,⁵ and medication errors may be a contributing factor.

Many published recommendations exist for reducing the incidence of perioperative MEs,⁶⁻⁸ some of which have been endorsed by national or international professional organizations such as the Anesthesia Patient Safety Foundation,⁶ the European Board of Anaesthesiology,⁸ and the Australian and New Zealand College of Anaesthetists.⁹ Often these recommendations offer conflicting advice – for example, some recommend the use of color-coded syringe labels⁷ while others recommend clear syringe labels.⁸ Some recommend that all syringes be labeled (even in emergency situations),⁹ whereas others state that it is acceptable to prepare and immediately administer a medication without a label if the syringe does not leave the provider's hand.⁸ It is imperative to standardize and optimize the recommendations for safe medication use.

1
2
3 Many of the existing recommendations that aim to prevent perioperative medication errors are
4 not feasible in middle and low income countries. While medication errors may be similar in type
5 and number between high income and middle or low income countries, the interventions needed
6 to improve medication safety may differ between these groups due to financial and resource
7 constraints. For example, one common recommendation to prevent syringe swaps in high
8 income countries is the use of pre-filled syringes that couple with point-of-care bar code
9 scanning and clinical decision support systems. This recommendation is not currently affordable
10 in low income countries.⁷ Instead, providers in low income countries could use a two-person
11 verification approach for high risk medications, and focus on the use of extra vigilance when
12 reading the labels on syringes and vials.⁷
13
14
15
16
17
18
19
20
21
22
23
24
25

26 Currently, no clear recommendations for perioperative medication safety exist that are tailored
27 to country income level, or that consider a hospital's existing processes and technologies. Our
28 study will address this gap by creating the first set of recommendations that are specifically
29 tailored to the World Bank's four country income groups: high, upper-middle, lower-middle, and
30 low income countries.¹⁰ Consequently, this study has been endorsed and deemed a priority by
31 the World Federation of Societies of Anesthesiologists (WFSA). Our specific aims are to:
32
33
34
35
36
37
38
39
40

- 41 1. Develop consensus-based recommendations for perioperative medication safety.
- 42 2. Prioritize the recommendations by their level of clinical importance and feasibility of
43 implementation in high, upper-middle, lower-middle and low income countries.
- 44 3. Disseminate the recommendations.
- 45 4. Evaluate the initial adoption of the recommendations in each country income group.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

Study Design:

The goal of this mixed-methods study is to create consensus-based recommendations for perioperative medication safety. The study will be conducted in five parts. First, we will develop a set of candidate recommendations using an extensive review of the literature.

Recommendations will address the entire medication use process (ordering, dispensing, preparing, administering, documenting and monitoring) in pre-operative holding areas, operating rooms and post-anesthesia recovery areas. Second, we will use the extensively studied RAND-UCLA Delphi Method^{9,11-14} to achieve consensus on the candidate perioperative medication safety recommendations. Third, we will prioritize the recommendations for implementation in each of the four country income groups. Fourth, we will disseminate these recommendations. Finally, we will use semi-structured interviews with a grounded theory analysis approach to assess the initial adoption of the recommendations. Our methodologic approach for each of these five activities is presented separately below.

Study Population and Recruitment:

Our expert panel will consist of 108 members, 27 from each of the World Bank's four country income groups: high, upper-middle, lower-middle, and low income (as defined by the World Bank Atlas method).¹⁰ Each of the four groups of 27 expert panel members will be comprised of anesthesiologists (N=17), surgeons (N=2), operating room nurses (N=2), nurse anesthetists (N=2), pharmacists (N=2) and medication safety experts (N=2).

To recruit anesthesiologist participants, the study team will contact each of the 134 national societies of anesthesiologists that are members of the WFSA. These member organizations represent anesthesiologists from over 150 countries, including those from 45 (32.6%) high income, 42 (30.4%) upper middle income, 34 (24.6%) lower middle income and 17 (12.3%) low

1
2
3 income countries.¹⁵ Each national society leadership will be asked to send an electronic
4
5 communication to their membership asking interested members to contact the research team to
6
7 participate in the study. This process will be repeated to recruit participants from surgical,
8
9 nursing and pharmacist national professional societies.
10

11 12 13 **Part 1: Development of Candidate Recommendations by Literature Review**

14
15 Our research team performed an extensive literature search to identify publications containing
16
17 recommendations for perioperative medication safety. Our search included PubMed (MeSH
18
19 terms Drug/Medication Error, Drug/Medication Safety, Operating Room, Anesthesia), and an
20
21 internet search for recommendations released by national agencies and professional societies
22
23 such as Anesthesia Patient Safety Foundation,⁶ the European Board of Anaesthesiology,⁸ and
24
25 the Australian and New Zealand College of Anaesthetists,⁹ and the World Health Organization.¹⁶
26
27 We created a database of all published recommendations, deleting duplicate recommendations.
28
29 This resulted in a final set of 133 recommendations, in the following categories: Standardization
30
31 (77, 57.9% of recommendations), Technology (9, 6.8% of recommendations), Medication Use
32
33 Process (42, 31.6% of recommendations) and Culture (5, 3.8% of recommendations). These
34
35 recommendations will serve as the candidate recommendations for our first round Delphi
36
37 survey.
38
39
40
41
42

43 **Part 2: Development of Medication Safety Recommendations using a Delphi Approach**

44
45 Round 1: We will use the extensively studied RAND-UCLA Delphi Method¹¹⁻¹⁴ to achieve
46
47 consensus on the perioperative medication safety recommendations, using the preliminary
48
49 candidate recommendations as a starting point. We will modify the Delphi Method to use
50
51 electronic surveys in order to allow participants to participate from remote locations. We will
52
53 develop electronic surveys using RedCAP (Nashville, USA), that will be sent to expert panel
54
55 members by email to ask them to rate the appropriateness of each candidate recommendation
56
57
58
59
60

1
2
3 on a 9-point scale, with a score of one denoting inappropriate and nine, appropriate. If a panel
4 member rates a recommendation six or below, they will be asked to provide feedback (free text)
5 to improve the recommendation. Recommendations with a median rating of 1-3 without any
6 disagreement among panel members will be discarded. Recommendations with median ratings
7 of 7-9 without disagreement will be included in our final recommendations. Those with median
8 ratings of 4-6 or any median with disagreement among panel members will be considered
9 uncertain. For non-English-speaking participants, surveys will be translated into the six official
10 WHO languages: Arabic, Chinese, English, French, Russian and Spanish.
11
12
13
14
15
16
17
18
19
20
21

22 Due to the unique medication safety hazards and a paucity of literature on medication safety in
23 low and middle income countries, the survey will also ask participants to provide additional
24 recommendations that we may not have captured in the survey. Recommendations suggested
25 by 5 or more of our expert panel members from a single country income group will be included
26 as candidate recommendations in the second round Delphi survey.
27
28
29
30
31
32
33
34

35 Round 2: A second electronic survey will be sent to the panel asking members to rate any new
36 recommendations that were suggested by more than 5 participants from a single country
37 income group. They will also be asked to re-rate the recommendations that were considered
38 uncertain based on the results of the first survey. These uncertain recommendations will be
39 revised for the second survey based on comments we receive from respondents on the first
40 survey. While the rating process for the second survey will be identical to the first survey, de-
41 identified comments and feedback from panel members who rated a recommendation 6 or less
42 in the first survey will be included for all panel members to consider as they re-assess their
43 ratings in the second survey. After the second survey, recommendations with median ratings of
44 1-3 without disagreement will be discarded and those with median ratings of 7-9 without
45 disagreement will be included in our final recommendations. If more than 10 recommendations
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 remain with median ratings of 4-6 or any median rating with disagreement among panel
4
5 members, a third and final Delphi survey will be created, with the same process as the Round 2
6
7 survey.
8
9

10 11 Data Analysis:

12
13 *Power Calculation:* Our expert panel will consist of 108 members, 27 from each of the four
14
15 country income groups. Using a two-sided confidence interval for one proportion test, a sample
16
17 size of 27 participants in each of the four country income groups (N=108 total in all four groups)
18
19 would yield a 95% confidence interval with a width equal to 0.3, assuming the sample proportion
20
21 of 0.85. This resulting 0.3 two-sided confidence interval width is equal to a confidence interval
22
23 having the lower limit of 0.66 and the upper limit of 0.96. Thus, our study will be sufficiently
24
25 powered with the sample size N=108 for a 95% chance that the true population rate of
26
27 agreement will lie between 66% and 96%, assuming the sample agreement rate among our
28
29 expert panel members is 85%.
30
31
32
33

34
35 Each of the four groups of 27 expert panel members will consist of 17 anesthesiologists and 2
36
37 non-anesthesiologists professionals from each of the following categories: surgeons, operating
38
39 room nurses, nurse anesthetists, pharmacists and medication safety experts. Thus, each non-
40
41 anesthesiologist professional will have a total sample size of 8 in all four country income groups.
42
43 The sample size of 8 non-anesthesiologist professionals will yield a power of 0.8 to detect a
44
45 minimum detectable effect size $d = 1.5$ using a two independent sample t-test with $\alpha = 0.05$.
46
47 The effect size corresponds to a mean difference among professions in rating of a
48
49 recommendation of 1.5-points, assuming a standard deviation of 1 rating point.
50
51
52
53

54 *IPRAS Method:* Due to the large size of our expert panel, we will use the Rand Corporation's
55
56 Interpercentile Range Adjusted for Symmetry (IPRAS) method to assess agreement between
57
58
59

1
2
3 panel members on each survey question during the Delphi Analyses.¹¹ Briefly, IPRAS involves
4 comparing the actual interpercentile range (10th to 90th percentile) of survey ratings to the
5 IRPAS. The interpercentile range is smaller when score distributions are asymmetric than when
6 they are symmetric. Thus, disagreement occurs when the actual interpercentile range is larger
7 than the IPRAS; all other cases will be classified as agreement.
8
9
10
11
12

13
14
15
16 *Inclusion of Additional Recommendations:* New recommendations suggested by 5 or more of
17 our expert panel members from a single country income group in the first round Delphi survey
18 will be included as candidate recommendations in the second round Delphi survey. If there is a
19 30% chance of a participant suggesting a new recommendation, there would be $27 \times 0.3 = 9$
20 newly suggested recommendations on average per country income group. Since 5 of our expert
21 panel members from a single country income group will need to suggest the same
22 recommendation for it to be included in the Delphi survey, we hypothesize that 1-2 new
23 recommendations from each country income group could be added to our total 133 candidate
24 recommendations, for a total of 3-6 new recommendations (a 2-4% increase). This will not affect
25 our panelist sample size estimation or statistical analytic method choices.
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Part 3: Prioritization of Recommendations by their level of clinical importance for** 40 **implementation in each of the country income groups**

41
42 A final electronic survey will be sent to participants asking them to rank each of the
43 recommendations selected by the Delphi Method on a scale from 1 to N=number of accepted
44 recommendations, according to its importance as a next step in improving medication safety in
45 each of low, lower-middle, upper-middle and high income country groups. When ranking by
46 importance, participants will consider the anticipated Reach, Effectiveness, Adoption,
47 Implementation and Maintenance for each recommendation (RE-AIM Framework).¹⁷⁻¹⁹ A rank
48 of 1 will denote the recommendation(s) with the highest importance considering these five RE-
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 AIM dimensions and N, the lowest importance. Panel members will be allowed to have tied
4 rankings within a country income group and will not be required to rank all the
5 recommendations. Unranked recommendations will be assigned the lowest rank, N.
6
7
8
9

10 11 Data Analysis:

12
13 *RE-AIM framework:* We will use the extensively studied RE-AIM framework, which defines the
14 impact of an intervention as the product of its Reach (proportion of the target population that
15 participates), Efficacy (success rate if implemented as intended; positive outcomes minus
16 negative outcomes), Adoption (proportion of settings/practices that adopt the intervention),
17 Implementation (extent to which the intervention is completely implemented as intended) and
18 Maintenance (extent to which the intervention is sustained over time).^{19,20} The product of these
19 five dimensions is called the public health impact score, and has been used to determine which
20 interventions are worth sustained investment, and which will work in real-world environments.¹⁸
21 RE-AIM dimensions can also be assessed at multiple points in time to track the impact of an
22 intervention. In Part 3, we will use the RE-AIM framework to prioritize each recommendation by
23 its importance as a next step in improving medication safety in each of the four country income
24 groups. In Part 5, we will use the RE-AIM framework as a practical measure of how well the
25 recommendations work in real-world settings in each income group, and to assess the impact of
26 the recommendations on global public health. This framework is well-suited for health care
27 innovation projects because it focuses on the validity of the intervention (in this case
28 recommendations), and guides the planning, conduct, evaluation and maintenance of
29 implementation of each recommendation.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49
50
51 *Individual rankings:* For each country income group, we will calculate the mean rank assigned
52 by the panel to each recommendation. Recommendations with a higher mean rank can be
53 interpreted as having a higher importance than those with a lower mean rank. To explore
54
55
56
57
58
59
60

1
2
3 differences in rankings between panel members from different country income groups, we will
4 use the Kruskal-Wallis test for each rule, with the Bonferroni correction to adjust for multiple
5 hypothesis testing.²¹ P values lower the $0.05/N$ will be considered statistically significant where
6
7
8
9
10 N is the number of recommendations ranked.

11
12
13 *Overall group ranking:* We will use a Condorcet ranking method called the Crowd Ranking
14 Kit^{22,23} to achieve an overall group ranking of recommendations for each of the four country
15 income groups. Briefly, for each possible pair of candidate recommendations within an income
16 group, we will determine whether at least as many panel members prioritized recommendation
17 A over B as prioritized recommendation B over A. The Condorcet Winner²⁴ is the
18 recommendation that is prioritized pairwise to all other recommendations. Condorcet cycles
19 occur when there is no clear preference among recommendations (e.g., the majority prioritize
20 recommendation A over B, B over C, and C over A).^{24,25} The Crowd Ranking Kit method
21 combines individual rankings into a unique hierarchy of ranked Condorcet cycles, which defines
22 the ordering and gives a ranked list of group preferences for each country income group.
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 *Graphical Representation:* With X survey responses, we will graph the importance of each
38 recommendation for each country income group in X-dimensional space, with the coordinates
39 for each recommendation being its rank assigned by the X panel members. Unranked
40 recommendations will be assigned the lowest rank $N = \text{number of recommendations}$. We will
41 illustrate the relative positions of the N recommendations in the X-dimensional space using a
42 statistical method often used in psychological and behavior research called ordinal
43 multidimensional scaling (MDS),²⁶⁻²⁸ which maps points in X-dimensional space to points in 2-
44 dimensional (2-D) space. We will define goodness of fit as 1-Kruskal's Stress²⁶ so that 100%
45 represents a perfect representation of the relative positions of the recommendations in two-
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 dimensional space. Fits higher than 80% are acceptable and fits higher than 90% are very
4
5 good.²⁹
6
7

8
9 For each country income group (and overall), we will identify clusters of recommendations that
10 are ranked similarly by panelists using hierarchical cluster analysis methods.^{30,31} We will
11 indicate the identified clusters on the 2-D feasibility map of the recommendations. This
12 sequential application of MDS and cluster analysis is common in behavioral research.³²⁻³⁴ On
13 the 2-D map, the horizontal axis is the axis that most separates the recommendations in X-
14 dimensional space. Given that our data points are rankings of importance, this axis will
15 represent the importance of implementing the recommendation in the given country income
16 group.
17
18
19
20
21
22
23
24
25

26 27 28 **Part 4: Dissemination, Diffusion and Adoption of the Recommendations** 29

30 While diffusion is the informal, peer-mediated, de-centralized spread of innovation,
31 dissemination is a more planned, formal, centralized approach to adoption of innovation.³⁵
32 Adoption of the prioritized recommendations for each of the four country income groups will be
33 encouraged by disseminating and diffusing the information using the following strategies:
34
35
36
37
38
39

- 40
41 • Endorsement of our recommendations by the WFSA
- 42
43 • Descriptions and links to our recommendations from the WFSA website
- 44
45 • Peer-reviewed manuscripts describing our methodology and our recommendations
- 46
47 • Presentations at influential national and international conferences, including the American
48 Society of Anesthesiologists, Anesthesia Patient Safety Foundation, and World Congress
49 of Anesthesiologists
- 50
51 • Presentations at hospital grand rounds in the US and globally
- 52
53
54
55
56
57
58
59
60

- Outreach to professional societies not only in high income countries, but also in middle and low income countries, to encourage use of the recommendations. This will include a description of the recommendations in their native language

Part 5: Evaluation of Initial Adoption using Semi-structure Interviews

Approximately twelve months after we disseminate the recommendations, we will conduct one-on-one semi-structured interviews with each participant to evaluate the initial adoption and implementation of the recommendations in each of the country income groups. Interviews will be audio recorded and conducted either in-person or by telephone/video conference.

The interview instrument shown in Figure 1 will be pilot tested and iteratively revised with our project steering committee members. It is based on the extensively studied RE-AIM framework,^{17,19,20} and includes: Introductory comments, questions with generic probes, questions with specific probes, final/summary questions, and closing statements.

Data Analysis:

Grounded Theory Analysis: In order to achieve thematic saturation (the point at which no new themes emerge from the interview data), we will interview at least 80 participants, n=20 from each of the four country income groups. We will follow the grounded theory approach to interpret qualitative data.³⁶⁻³⁹ Audio recordings of interviews will be transcribed verbatim, reviewed/corrected for transcription accuracy and removal/masking of identifying information, and entered into ATLAS.ti software (Scientific Software Development, Berlin) for coding and analysis. Our study team will regularly review themes and emergent findings with the project steering committee. We will repeatedly look at alternative explanations for interpretations of data, and rule them out or modify our initial interpretations. We will code data into categories

1
2
3 based on emergent themes. This iterative, analytic and reflective process will be conducted as
4 interview transcripts become available, allowing for modification of the coding scheme as well
5 as assuring that thematic saturation is reached.
6
7
8
9

10 11 **Patient and Public Involvement:**

12 Patients and the public were incorporated into our study design in several ways. First,
13 recommendations for perioperative medication safety that are in the public domain were
14 included as candidate recommendation for this study. Second, we incorporated national
15 professional societies (for anesthesiologists, surgeons, nurses, nurse anesthetists and
16 pharmacists) from around the world into our recruitment strategy, as described in the Study
17 Population and Recruitment section. Third, by making our recommendations publicly available,
18 we will involve patients and the public in the diffusion and dissemination of our
19 recommendations.
20
21
22
23
24
25
26
27
28
29
30
31

32 **ETHICS AND DISSEMINATION**

33 This study was approved by the Human Research Committee/Institutional Review Board at
34 Partners Healthcare (2019P003567), and is registered on clinicaltrials.gov (NCT04240301). The
35 study will be overseen by a multidisciplinary, international steering committee, including
36 members from North America, Latin America, Europe, New Zealand, Asia and Africa.
37
38
39
40
41
42
43
44

45 This project will create and disseminate the first consensus-based recommendations for
46 perioperative medication safety that are tailored to country income level, using the World Bank's
47 four country income groups: high (includes the US), upper-middle, lower-middle and low
48 income.^{10 10 14} The project will include the entire medication use process (ordering, dispensing,
49 preparing, administering, documenting and monitoring) in preoperative holding areas, operating
50 rooms and post-anesthesia recovery areas. The resulting recommendations will make surgery
51
52
53
54
55
56
57
58
59
60

1
2
3 safer for patients not only in high income countries but also in upper-middle, lower-middle and
4
5 low income countries around the world.
6
7

8
9 By creating the first set of recommendations that are specifically tailored to a country's income
10 and resource level, we will facilitate the successful dissemination and diffusion of our
11 recommendations. Greenhalgh and colleagues performed an extensive literature review on
12 adoption of innovation in health care³⁵ and found that diffusion and dissemination programs
13 have been most effective when they:
14
15
16
17
18

- 19
20
21
22 1. Incorporate potential adopters' needs and perspectives, with particular attention to
23 the cost-benefit tradeoff. We will achieve this in Part 2 via the Delphi Method, which
24 will incorporate the perspectives and recommendations of all participants, with equal
25 representation from high, upper-middle, lower-middle and low income countries.
26
27
28
29
30
31
- 32
33 2. Tailor different strategies to different demographic, structural and cultural groups,
34 which we will achieve in Part 3: Prioritize the recommendations by their level of
35 clinical importance for implementation in high, upper-middle, lower-middle and low
36 income countries.
37
38
39
40
41
42
- 43
44 3. Use appropriate communication style and channels, which we will achieve via i)
45 diffusion that is facilitated by our large, international group of participants, and ii)
46 dissemination that is facilitated by the participation of and endorsement by the
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

These strategies will ensure widespread diffusion and dissemination of our recommendations,
and thereby change the culture of medication safety, which currently leaves low resource

1
2
3 countries behind. Our inclusion of targeted recommendations for these areas will provide a
4 valuable resource for policy-makers, hospital administrators and frontline healthcare providers
5 to reduce the incidence of medication errors and their associated patient harm. Also, our
6 prioritization of the recommendations will allow easy identification of the most important
7 recommendations for future evaluation by randomized controlled trial. Finally, adoption of the
8 recommendations will make surgery and anesthesia safer both in the US and around the world.
9
10
11
12
13
14
15
16
17

18 The recommendations generated by this project will be shared globally via publication in peer-
19 reviewed journals, and descriptions and links on the websites of the World Federation of
20 Societies of Anesthesiologists and other professional organizations. Our findings will also be
21 presented at national and international meetings, and we will use grass-roots diffusion methods
22 via our large, international group of participants.
23
24
25
26
27
28
29

30 This project is important because it will make surgery safer for patients globally by creating and
31 disseminating the first consensus-based recommendations for perioperative medication safety
32 that are tailored to country income level. Widespread diffusion and dissemination of the resulting
33 recommendations has the potential to change the culture of medication safety, which currently
34 leaves low resource areas behind. Our inclusion of targeted recommendations for these areas
35 will provide a valuable resource for policy-makers, hospital administrators and frontline
36 healthcare providers to reduce the incidence of medication errors and their associated patient
37 harm.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Merry AF, Webster CS, Hannam J, et al. Multimodal system designed to reduce errors in recording and administration of drugs in anaesthesia: prospective randomised clinical evaluation. *BMJ*. 2011;343:d5543.
2. Nanji KC, Patel A, Shaikh S, Seger DL, Bates DW. Evaluation of perioperative medication errors and adverse drug events. *Anesthesiology*. 2016;124(1):25-34.
3. Fasting S, Gisvold SE. Adverse drug errors in anesthesia, and the impact of coloured syringe labels. *Canadian Journal of Anaesthesia*. 2000;47(11):1060.
4. Cooper JB, Newbower RS, Kitz RJ. An analysis of major errors and equipment failures in anesthesia management: Considerations for prevention and detection. *Anesthesiology*. 1984;60(1):34-42.
5. Melnick ER, Dyrbye LN, Sinsky CA, et al. The Association Between Perceived Electronic Health Record Usability and Professional Burnout Among US Physicians. *Mayo Clin Proc*. 2019.
6. Eichhorn J. APSF Hosts Medication Safety Conference. *Anesthesia Patient Safety Foundation Newsletter*. 2010;25(1):1-20.
7. Wahr JA, Abernathy J, Lazarra E, et al. Medication safety in the operating room: Literature and expert-based recommendations. *British Journal of Anaesthesia*. 2016;118(1):32-43.
8. Whitaker D, Brattebo G, Trenkler S, et al. The European Board of Anaesthesiology recommendations for safe medication practice: First update. *European Journal of Anaesthesiology*. 2017;34(1):4-7.
9. Guidelines for the Safe Management and Use of Medications in Anaesthesia. *Australian and New Zealand College of Anaesthetists*. 2017.
10. World Bank Country and Lending Groups. The World Bank. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>. Published 2019. Accessed Sept 24, 2019.
11. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR. *The RAND/UCLA appropriateness method user's manual*. RAND Corporation;2001.
12. Hinkelbein J, Lamperti M, Akeson J, et al. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. *European Journal of Anaesthesiology*. 2018;35(1):6-24.
13. Mangione-Smith R, DeCristofaro AH, Setodji CM, et al. The quality of ambulatory care delivered to children in the United States. *New England Journal of Medicine*. 2007;357(15):1515-1523.
14. SooHoo NF, Lieberman JR, Farnig E, Park S, Jain S, Ko CY. Development of quality of care indicators for patients undergoing total hip or total knee replacement. *BMJ Quality and Safety*. 2011;20(2):153-157.
15. World Federation of Societies of Anesthesiologists. Member Societies. World Federation of Societies of Anesthesiologists. Web site. <https://www.wfsahq.org/about-us/member-societies>. Published 2019. Accessed.
16. World Health Organization. *WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings*. World Health Organization; 2016.
17. Glasgow RE, Harden SM, Gaglio B, et al. RE-AIM planning and evaluation framework: Adapting to new science and practice with a 20-year review. *Front Public Health*. 2019;7:64.
18. Hayes C, O'Shea M, Foley-Nolan C, McCarthy M, Harrington J. Barriers and facilitators to adoption, implementation and sustainment of obesity prevention interventions in schoolchildren—a DEDIPAC case study. *BMC Public Health*. 2019;19(1):198.

19. RE-AIM. RE-AIM: Reach, Effectiveness, Adoption, Implementation, Maintenance. RE-AIM. Web site. <http://www.re-aim.org/>. Published 2019. Accessed.
20. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: The RE-AIM framework. *American Journal of Public Health*. 1999;89(9):1322-1327.
21. Hoffman JI. *Biostatistics for medical and biomedical practitioners*. San Diego, CA, USA: Academic Press; 2015.
22. Pagel C, Brown KL, McLeod I, et al. Selection by a panel of clinicians and family representatives of important early morbidities associated with paediatric cardiac surgery suitable for routine monitoring using the nominal group technique and a robust voting process. *BMJ open*. 2017;7(5):e014743.
23. Utley M, Gallivan S, Mills M, Mason M, Hargraves C. A consensus process for identifying a prioritised list of study questions. *Health Care Management Science*. 2007;10(1):105-110.
24. Young HP. Condorcet's theory of voting. *American Political Science Review*. 1988;82(4):1231-1244.
25. Gehrlein WV. Condorcet's paradox. *Theory and Decision*. 1983;15(2):161-197.
26. Borg I, Groenen PJ, Mair P. *Applied multidimensional scaling*. Springer Science and Business Media; 2012.
27. Hout MC, Papesh MH, Goldinger SD. Multidimensional scaling. *Wiley Interdisciplinary Reviews: Cognitive Science*. 2013;4(1):93-103.
28. Mugavin ME. Multidimensional scaling: A brief overview. *Nursing Research*. 2008;57(1):64-68.
29. Mair P, Borg I, Rusch T. Goodness-of-fit assessment in multidimensional scaling and unfolding. *Multivariate Behavioral Research*. 2016;51(6):772-789.
30. Garson GD. *Cluster Analysis*. Asheboro, NC, USA: Statistical Publishing Associates; 2014.
31. Mirkin B. Clustering: A data recovery approach. In. Vol 19: Chapman and Hall/CRC, Boca Raton, FL, USA; 2012.
32. Hanke K, Liu JH, Sibley CG, et al. "Heroes" and "villains" of world history across cultures. *PLoS One*. 2015;10(2):e0115641.
33. Beurskens AJ, Swinkels RA, Pool JJ, Batterham RW, Osborne RH, de Vet HC. The burden of neck pain: Its meaning for persons with neck pain and healthcare providers, explored by concept mapping. *Quality of Life Research*. 2016;25(5):1219-1225.
34. Nowicki EA, Brown JD, Dare L. Educators' evaluations of children's ideas on the social exclusion of classmates with intellectual and learning disabilities. *Journal of Applied Research in Intellectual Disabilities*. 2018;31(1):e154-e163.
35. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: Systematic review and recommendations. *Milbank Q*. 2004;82(4):581-629.
36. Nanji KC, Rothschild JM, Boehne JJ, Keohane CA, Ash JS, Poon EG. Unrealized potential and residual consequences of electronic prescribing on pharmacy workflow in the outpatient pharmacy. *Journal of the American Medical Informatics Association*. 2014;21(3):481-486.
37. Ash JS, Sittig DF, Dykstra R, Campbell E, Guappone K. The unintended consequences of computerized provider order entry: Findings from a mixed methods exploration. *International journal of medical informatics*. 2009;78(Suppl 1):S69-76.
38. Glaser B, Strauss A. *The discovery of grounded theory: Strategies for qualitative research*. Chicago, IL, USA: Aldine; 1967.
39. Miles MB, Huberman AM. *Qualitative data analysis: An expanded sourcebook*. 2 ed. Thousand Oaks, CA, USA: Sage Publications; 1994.

AUTHOR CONTRIBUTIONS

Author KCN contributed to study design, statistical plan, drafting and revising the manuscript.

Author AFM contributed to study design, statistical plan, and revising the manuscript. Author SS contributed to drafting and revising the manuscript. Author CP contributed to study design, statistical plan, and revising the manuscript. Author HD contributed to the statistical plan and revising the manuscript. Author JW contributed to study design, statistical plan, and revising the manuscript. Author AG contributed to study design, statistical plan, and revising the manuscript. Author BAO contributed to study design, statistical plan, and revising the manuscript.

COMPETING INTERESTS

Dr. Nanji receives author royalties from UpToDate, Inc (Waltham MA). Dr. Merry has shares in Safersleep LLC (Auckland NZ) and chairs its Board. Dr. Wahr received speaker honoraria from the Anesthesia Patient Safety Foundation (Rochester MN) and the Aspen Institute (Aspen CO). Dr. Gelb receives consulting fees from Masimo Inc (Irvine CA) and Haisco Pharmaceutical (Shannan, China). He is also Secretary of the World Federation of Societies of Anesthesiologists (London UK). Dr. Orser serves on the Board of Directors of the Institute for Safe Medication Practices (ISMP) Canada (Toronto Canada). The remaining authors have no competing interests.

FUNDING STATEMENT

This work was supported by a grant from the Agency for Healthcare Research and Quality (AHRQ, Rockville, MD, #1K08HS024764-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ. The did not AHRQ have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

FIGURE 1: PRELIMINARY INTERVIEW INSTRUMENT

Introductory comments: We will thank participants, obtain verbal informed consent for the interview and audio recording, explain that the interview is confidential, obtain demographic information, and begin audio recording.

Questions with generic probes: We will start with a general open-ended question, “Please tell me how the recommendations were implemented.” To help elicit information, we will use additional probes such as “Please tell me more about...”, “Help me understand...”, and “Other participants have said XXX. What do you think?”

Questions with specific probes:

Reach: a) How many of your colleagues would you estimate are aware of the recommendations (none, a few, half, most, all)? b) How has communication and collaboration related to medication safety changed from pre-recommendations to the present?

Efficacy: a) How effective are the recommendations (What were the problems and how did you overcome them?) b) Were any unintended consequences related to patient safety or workflow noted? c) Were there any secondary benefits (e.g., enhanced safety awareness)? d) Does your hospital maintain an incident reporting system? If yes, have you noticed a change in the number, type or severity of medication-related incidents reported? e) Does your country maintain a national incident reporting system? If yes, have you noticed a change in the number, type or severity of medication-related incidents reported?

Adoption: a) Where is your center in the implementation process of the recommendations (not started, early stages, middle, almost complete, complete)? b) What about other centers in your area (not started, early stages, middle, almost complete, complete)?

Implementation: a) What barriers to implementation were identified and how were they addressed? b) What enabling factors were identified and how were they used? (e.g., human “champions”, pre-existing robust QI programs) c) Were any workarounds developed to avoid a recommendation? What were they? What issues prompted providers to resort to a workaround? d) What resources were used to support implementation (existing structure such as a QI team, or a new structure such as a new implementation committee)? e) What surprised you because it went so smoothly? f) Did implementation take longer than you thought?

Maintenance: a) How did the recommendations integrate within pre-implementation workflows (seamless, minor “add on,” or required major changes)? b) What resistance have you encountered (e.g., naysayers, lack of resources, etc)?

Final questions: a) What haven’t I asked that will be helpful for us to know? b) Do you have any other comments about what we have discussed today?

Closing statements: Thank you, re-iterate that the interview is confidential, provide our email and telephone numbers in case the participant would like to contact us to add information.

BMJ Open

Global PRoMiSe (Perioperative Recommendations for Medication Safety): Protocol for a mixed-methods study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038313.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Apr-2020
Complete List of Authors:	Nanji, Karen; Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine Merry, Alan; Auckland City Hospital, Dept of Anaesthesiology Shaikh, Sofia; Massachusetts General Hospital, Pagel, Christina; University College London Deng, Hao; Massachusetts General Hospital, Department of Anesthesia Critical Care and Pain Medicine Wahr, Joyce; University of Minnesota Medical Center, Anesthesiology Gelb, Adrian; University of California San Francisco, Anesthesia and Perioperative Care Orser, Beverley; Sunnybrook Health Sciences Centre, Anesthesia
Primary Subject Heading:	Research methods
Secondary Subject Heading:	Anaesthesia, Global health, Health services research, Public health
Keywords:	Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Adult anaesthesia < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Global PRoMiSe (Perioperative Recommendations for Medication Safety):

Protocol for a mixed-methods study

Nanji KC^{1, 2, 3}, Merry AF^{4, 5}, Shaikh S¹, Pagel C⁶, Deng H¹, Wahr J⁷, Gelb AW⁸, and Orser
BA^{9,10}.

1. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.
2. Harvard Medical School, Boston, MA, USA.
3. Partners Healthcare Systems, Inc., Wellesley, MA, USA.
4. Department of Anaesthesiology, School of Medicine, University of Auckland, Auckland, New Zealand.
5. Department of Anaesthesia, Auckland City Hospital, Auckland, New Zealand.
6. Clinical Operational Research Unit, University College London, London, UK.
7. Department of Anesthesiology, University of Minnesota, Minneapolis, MN, USA.
8. Department of Anesthesia & Perioperative Care, University of California San Francisco, San Francisco, CA, USA.
9. Department of Anesthesia, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
10. Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.

Corresponding Author:

Karen C. Nanji, MD MPH

Department of Anesthesia, Critical Care and Pain Medicine

Massachusetts General Hospital

55 Fruit Street, Boston, MA 02114

KNANJI@mgh.harvard.edu

T: 617.838.6690

Word Count: 3,822

Key Words: Anesthesia, Medication Errors, Patient Safety

ABSTRACT

Introduction: Medication errors (MEs), which occur commonly in the perioperative period, have the potential to cause patient harm or death. Many published recommendations exist for preventing perioperative MEs; however, many of these recommendations conflict and are often not applicable to middle and low income countries. The goal of this study is to develop and disseminate consensus-based recommendations for perioperative medication safety that are tailored to country income level.

Methods and Analysis: The primary site of this mixed-methods study is Massachusetts General Hospital/Harvard Medical School. Participants include 108 international medication safety experts, 27 from each of the World Bank's four country income groups (high, upper-middle, lower-middle and low income). Using the Delphi method, participants will rate the appropriateness of candidate medication safety recommendations by completing online surveys using REDCAP. We will use Condorcet ranking methods to prioritize the final recommendations for each country income group. We will execute a comprehensive dissemination strategy for the recommendations across each country income group. Finally, we will conduct semi-structured interviews with our participants to evaluate the initial adoption and implementation of the recommendations in each country income group.

Ethics and Dissemination: This study was approved by the Human Research Committee/Institutional Review Board at Partners Healthcare (2019P003567), and is registered on clinicaltrials.gov (NCT04240301). Findings will be published in peer-reviewed journals and presented at local and international conferences.

ARTICLE SUMMARY

Strengths and limitations of this study:

- Robust mixed-methods study design to include a large number of participants
- Recommendations that target the entire perioperative medication use process.
- First medication safety initiative to include equal representation from each of the World Bank's four country income groups, allowing for generalizability of recommendations internationally, regardless of country income level.
- World Federation of Societies of Anesthesiologists (WFSA) endorsed the study and deemed it to be a priority.
- While we will translate all study documents and have interpreters available in each of the World Health Organizations six official languages (Arabic, Chinese, English, French, Russian and Spanish), language barriers may impact the participation of experts who are not fluent in any of these languages.

INTRODUCTION

Perioperative medication errors (MEs) have the potential to cause serious patient harm.

Growing evidence indicates that MEs and adverse medication events (AMEs) are as common in the perioperative setting as they are in other hospital environments.^{1,2} However, medication use in the perioperative setting presents particular challenges to patient safety. The delivery of medications in the operating room usually bypasses standard safety checks, such as electronic physician order entry systems that include clinical decision support and alerts, approvals by pharmacists, and double-checks by nurses prior to medication administration. Furthermore, the high-stress, time-sensitive nature of work in the operating room can contribute to high rates of MEs and errors of greater severity in the operating room compared with other clinical settings. In the operating room, syringe swaps, ampoule swaps, and wrong dose errors can cause serious harm.³ In fact, the most frequently cited critical adverse events in anesthesia are MEs.⁴⁻⁶ Surprisingly, after decades of decline, the worldwide death rate during anesthesia is once again increasing,⁷ and medication errors may be a contributing factor.

Many published recommendations exist for reducing the incidence of perioperative MEs,⁸⁻¹⁰ some of which have been endorsed by national or international professional organizations such as the Anesthesia Patient Safety Foundation,⁸ the European Board of Anaesthesiology,¹⁰ and the Australian and New Zealand College of Anaesthetists.¹¹ Often these recommendations offer conflicting advice – for example, some recommend that all syringes be labeled (even when possible in emergency situations),¹¹ whereas others endorse preparing and immediately administering a medication without a label if the syringe does not leave the provider's hand.¹⁰ It is imperative to standardize and optimize the recommendations for safe medication use.

Many of the existing recommendations that aim to prevent perioperative medication errors are not feasible in middle and low income countries. While medication errors may be similar in type

1
2
3 and number between high income and middle or low income countries, the interventions needed
4 to improve medication safety may differ between these groups due to financial and resource
5 constraints. For example, one common recommendation to prevent syringe swaps in high
6 income countries is the use of pre-filled syringes that couple with point-of-care bar code
7 scanning and clinical decision support systems. This recommendation is not currently affordable
8 in low income countries.⁹ Instead, providers in low income countries could use a two-person
9 verification approach for high risk medications, and focus on the use of extra vigilance when
10 reading the labels on syringes and vials.⁹
11
12
13
14
15
16
17
18
19
20
21

22 Currently, no clear recommendations for perioperative medication safety exist that are tailored
23 to country income level, or that consider a hospital's existing processes and technologies. Our
24 study will address this gap by creating the first set of recommendations that are specifically
25 tailored to the World Bank's four country income groups: high, upper-middle, lower-middle, and
26 low income countries.¹² Consequently, this study has been endorsed and deemed a priority by
27 the World Federation of Societies of Anesthesiologists (WFSA). Our specific aims are to:
28
29
30
31
32
33
34
35
36

- 37 1. Develop consensus-based recommendations for perioperative medication safety.
- 38 2. Prioritize the recommendations by their level of clinical importance and feasibility of
39 implementation in high, upper-middle, lower-middle and low income countries.
40
- 41 3. Disseminate the recommendations.
42
- 43 4. Evaluate the initial adoption of the recommendations in each country income group.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

Study Design:

The goal of this mixed-methods study is to create consensus-based recommendations for perioperative medication safety. The study will be conducted in five parts. First, we will develop a set of candidate recommendations using an extensive review of the literature.

Recommendations will address the entire medication use process (ordering, dispensing, preparing, administering, documenting and monitoring) in pre-operative holding areas, operating rooms and post-anesthesia recovery areas. Second, we will use the extensively studied RAND-UCLA Delphi Method^{11,13-16} to achieve consensus on the candidate perioperative medication safety recommendations. Third, we will prioritize the recommendations for implementation in each of the four country income groups. Fourth, we will disseminate these recommendations. Finally, we will use semi-structured interviews with a grounded theory analysis approach to assess the initial adoption of the recommendations. Our methodologic approach for each of these five activities is presented separately below.

Study Population and Recruitment:

Our expert panel will consist of 108 members, 27 from each of the World Bank's four country income groups: high, upper-middle, lower-middle, and low income (as defined by the World Bank Atlas method).¹² Each of the four groups of 27 expert panel members will be comprised of anesthesiologists (N=17), surgeons (N=2), operating room nurses (N=2), nurse anesthetists (N=2), pharmacists (N=2) and medication safety experts (N=2).

To recruit anesthesiologist participants, the study team will contact each of the 134 national societies of anesthesiologists that are members of the WFSA. These member organizations represent anesthesiologists from over 150 countries, including those from 45 (32.6%) high income, 42 (30.4%) upper middle income, 34 (24.6%) lower middle income and 17 (12.3%) low

1
2
3 income countries.¹⁷ Each national society leadership will be asked to send an electronic
4
5 communication to their membership asking interested members to contact the research team to
6
7 participate in the study. This process will be repeated to recruit participants from surgical,
8
9 nursing and pharmacist national professional societies.
10

11 12 13 **Part 1: Development of Candidate Recommendations by Literature Review**

14
15 Our research team performed an extensive literature search to identify publications containing
16
17 recommendations for perioperative medication safety. Our search included PubMed (MeSH
18
19 terms Drug/Medication Error, Drug/Medication Safety, Operating Room, Anesthesia), and an
20
21 internet search for recommendations released by national agencies and professional societies
22
23 such as Anesthesia Patient Safety Foundation,⁸ the European Board of Anaesthesiology,¹⁰ the
24
25 Australian and New Zealand College of Anaesthetists,¹¹ and the World Health Organization.¹⁸
26
27 We created a database of all published recommendations, deleting duplicate recommendations.
28
29 This resulted in a final set of 133 recommendations, in the following categories: Standardization
30
31 (77, 57.9% of recommendations), Technology (9, 6.8% of recommendations), Medication Use
32
33 Process (42, 31.6% of recommendations) and Culture (5, 3.8% of recommendations). These
34
35 recommendations will serve as the candidate recommendations for our first round Delphi
36
37 survey.
38
39
40
41
42

43 **Part 2: Development of Medication Safety Recommendations using a Delphi Approach**

44
45 Round 1: We will use the extensively studied RAND-UCLA Delphi Method¹³⁻¹⁶ to achieve
46
47 consensus on the perioperative medication safety recommendations, using the preliminary
48
49 candidate recommendations as a starting point. We will modify the Delphi Method to use
50
51 electronic surveys in order to allow participants to participate from remote locations. We will
52
53 develop electronic surveys using RedCAP (Nashville, USA), that will be sent to expert panel
54
55 members by email to ask them to rate the appropriateness of each candidate recommendation
56
57
58
59
60

1
2
3 on a 9-point scale, with a score of one denoting inappropriate and nine, appropriate. If a panel
4 member rates a recommendation six or below, they will be asked to provide feedback (free text)
5 to improve the recommendation. Recommendations with a median rating of 1-3 without any
6 disagreement among panel members will be discarded. Recommendations with median ratings
7 of 7-9 without disagreement will be included in our final recommendations. Those with median
8 ratings of 4-6 or any median with disagreement among panel members will be considered
9 uncertain. For non-English-speaking participants, surveys will be translated into the six official
10 WHO languages: Arabic, Chinese, English, French, Russian and Spanish.
11
12
13
14
15
16
17
18
19
20
21

22 Due to the unique medication safety hazards and a paucity of literature on medication safety in
23 low and middle income countries, the survey will also ask participants to provide additional
24 recommendations that we may not have captured in the survey. Recommendations suggested
25 by 5 or more of our expert panel members from a single country income group will be included
26 as candidate recommendations in the second round Delphi survey.
27
28
29
30
31
32
33
34

35 Round 2: A second electronic survey will be sent to the panel asking members to rate any new
36 recommendations that were suggested by more than 5 participants from a single country
37 income group. They will also be asked to re-rate the recommendations that were considered
38 uncertain based on the results of the first survey. These uncertain recommendations will be
39 revised for the second survey based on comments we receive from respondents on the first
40 survey. While the rating process for the second survey will be identical to the first survey, de-
41 identified comments and feedback from panel members who rated a recommendation 6 or less
42 in the first survey will be included for all panel members to consider as they re-assess their
43 ratings in the second survey. After the second survey, recommendations with median ratings of
44 1-3 without disagreement will be discarded and those with median ratings of 7-9 without
45 disagreement will be included in our final recommendations. If more than 10 recommendations
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 remain with median ratings of 4-6 or any median rating with disagreement among panel
4
5 members, a third and final Delphi survey will be created, with the same process as the Round 2
6
7 survey.
8
9

10 11 Data Analysis:

12
13 *Power Calculation:* Our expert panel will consist of 108 members, 27 from each of the four
14
15 country income groups. Using a two-sided confidence interval for one proportion test, a sample
16
17 size of 27 participants in each of the four country income groups (N=108 total in all four groups)
18
19 would yield a 95% confidence interval with a width equal to 0.3, assuming the sample proportion
20
21 of 0.85. This resulting 0.3 two-sided confidence interval width is equal to a confidence interval
22
23 having the lower limit of 0.66 and the upper limit of 0.96. Thus, our study will be sufficiently
24
25 powered with the sample size N=108 for a 95% chance that the true population rate of
26
27 agreement will lie between 66% and 96%, assuming the sample agreement rate among our
28
29 expert panel members is 85%.
30
31
32
33

34
35 Each of the four groups of 27 expert panel members will consist of 17 anesthesiologists and 2
36
37 non-anesthesiologists professionals from each of the following categories: surgeons, operating
38
39 room nurses, nurse anesthetists, pharmacists and medication safety experts. Thus, each non-
40
41 anesthesiologist professional will have a total sample size of 8 in all four country income groups.
42
43 The sample size of 8 non-anesthesiologist professionals will yield a power of 0.8 to detect a
44
45 minimum detectable effect size $d = 1.5$ using a two independent sample t-test with $\alpha = 0.05$.
46
47 The effect size corresponds to a mean difference among professions in rating of a
48
49 recommendation of 1.5-points, assuming a standard deviation of 1 rating point.
50
51
52
53

54
55 *IPRAS Method:* Due to the large size of our expert panel, we will use the Rand Corporation's
56
57 Interpercentile Range Adjusted for Symmetry (IPRAS) method to assess agreement between
58
59

1
2
3 panel members on each survey question during the Delphi Analyses.¹³ Briefly, IPRAS involves
4 comparing the actual interpercentile range (10th to 90th percentile) of survey ratings to the
5 IRPAS. The interpercentile range is smaller when score distributions are asymmetric than when
6 they are symmetric. Thus, disagreement occurs when the actual interpercentile range is larger
7 than the IPRAS; all other cases will be classified as agreement.
8
9
10
11
12

13
14
15
16 *Inclusion of Additional Recommendations:* New recommendations suggested by 5 or more of
17 our expert panel members from a single country income group in the first round Delphi survey
18 will be included as candidate recommendations in the second round Delphi survey. If there is a
19 30% chance of a participant suggesting a new recommendation, there would be $27 \times 0.3 = 9$
20 newly suggested recommendations on average per country income group. Since 5 of our expert
21 panel members from a single country income group will need to suggest the same
22 recommendation for it to be included in the Delphi survey, we hypothesize that 1-2 new
23 recommendations from each country income group could be added to our total 133 candidate
24 recommendations, for a total of 3-6 new recommendations (a 2-4% increase). This will not affect
25 our panelist sample size estimation or statistical analytic method choices.
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Part 3: Prioritization of Recommendations by their level of clinical importance for** 40 **implementation in each of the country income groups**

41
42 A final electronic survey will be sent to participants asking them to rank each of the
43 recommendations selected by the Delphi Method on a scale from 1 to N=number of accepted
44 recommendations, according to its importance as a next step in improving medication safety in
45 each of low, lower-middle, upper-middle and high income country groups. When ranking by
46 importance, participants will consider the anticipated Reach, Effectiveness, Adoption,
47 Implementation and Maintenance for each recommendation (RE-AIM Framework).¹⁹⁻²¹ A rank
48 of 1 will denote the recommendation(s) with the highest importance considering these five RE-
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 AIM dimensions and N, the lowest importance. Panel members will be allowed to have tied
4 rankings within a country income group and will not be required to rank all the
5 recommendations. Unranked recommendations will be assigned the lowest rank, N.
6
7
8
9

10 11 Data Analysis:

12
13 *RE-AIM framework:* We will use the extensively studied RE-AIM framework, which defines the
14 impact of an intervention as the product of its Reach (proportion of the target population that
15 participates), Efficacy (success rate if implemented as intended; positive outcomes minus
16 negative outcomes), Adoption (proportion of settings/practices that adopt the intervention),
17 Implementation (extent to which the intervention is completely implemented as intended) and
18 Maintenance (extent to which the intervention is sustained over time).^{21,22} The product of these
19 five dimensions is called the public health impact score, and has been used to determine which
20 interventions are worth sustained investment, and which will work in real-world environments.²⁰
21 RE-AIM dimensions can also be assessed at multiple points in time to track the impact of an
22 intervention. In Part 3, we will use the RE-AIM framework to prioritize each recommendation by
23 its importance as a next step in improving medication safety in each of the four country income
24 groups. In Part 5, we will use the RE-AIM framework as a practical measure of how well the
25 recommendations work in real-world settings in each income group, and to assess the impact of
26 the recommendations on global public health. This framework is well-suited for health care
27 innovation projects because it focuses on the validity of the intervention (in this case
28 recommendations), and guides the planning, conduct, evaluation and maintenance of
29 implementation of each recommendation.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51 *Individual rankings:* For each country income group, we will calculate the mean rank assigned
52 by the panel to each recommendation. Recommendations with a higher mean rank can be
53 interpreted as having a higher importance than those with a lower mean rank. To explore
54
55
56
57
58
59

1
2
3 differences in rankings between panel members from different country income groups, we will
4 use the Kruskal-Wallis test for each rule, with the Bonferroni correction to adjust for multiple
5 hypothesis testing. P values lower the 0.05/N will be considered statistically significant where N
6 is the number of recommendations ranked.
7
8
9
10

11
12
13 *Overall group ranking:* We will use a Condorcet ranking method called the Crowd Ranking
14 Kit^{23,24} to achieve an overall group ranking of recommendations for each of the four country
15 income groups. Briefly, for each possible pair of candidate recommendations within an income
16 group, we will determine whether at least as many panel members prioritized recommendation
17 A over B as prioritized recommendation B over A. The Condorcet Winner²⁵ is the
18 recommendation that is prioritized pairwise to all other recommendations. Condorcet cycles
19 occur when there is no clear preference among recommendations (e.g., the majority prioritize
20 recommendation A over B, B over C, and C over A).^{25,26} The Crowd Ranking Kit method
21 combines individual rankings into a unique hierarchy of ranked Condorcet cycles, which defines
22 the ordering and gives a ranked list of group preferences for each country income group.
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 *Graphical Representation:* With X survey responses, we will graph the importance of each
38 recommendation for each country income group in X-dimensional space, with the coordinates
39 for each recommendation being its rank assigned by the X panel members. Unranked
40 recommendations will be assigned the lowest rank N = number of recommendations. We will
41 illustrate the relative positions of the N recommendations in the X-dimensional space using a
42 statistical method often used in psychological and behavior research called ordinal
43 multidimensional scaling (MDS),²⁷⁻²⁹ which maps points in X-dimensional space to points in 2-
44 dimensional (2-D) space. We will define goodness of fit as 1-Kruskal's Stress so that 100%
45 represents a perfect representation of the relative positions of the recommendations in two-
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 dimensional space. Fits higher than 80% are acceptable and fits higher than 90% are very
4
5 good.³⁰
6
7

8
9 For each country income group (and overall), we will identify clusters of recommendations that
10 are ranked similarly by panelists using hierarchical cluster analysis methods.^{31,32} We will
11 indicate the identified clusters on the 2-D feasibility map of the recommendations. This
12 sequential application of MDS and cluster analysis is common in behavioral research.³³⁻³⁵ On
13 the 2-D map, the horizontal axis is the axis that most separates the recommendations in X-
14 dimensional space. Given that our data points are rankings of importance, this axis will
15 represent the importance of implementing the recommendation in the given country income
16 group.
17
18
19
20
21
22
23
24
25

26 27 28 **Part 4: Dissemination, Diffusion and Adoption of the Recommendations** 29

30 While diffusion is the informal, peer-mediated, de-centralized spread of innovation,
31 dissemination is a more planned, formal, centralized approach to adoption of innovation.³⁶
32 Adoption of the prioritized recommendations for each of the four country income groups will be
33 encouraged by disseminating and diffusing the information using the following strategies:
34
35
36
37
38
39

- 40
41 • Endorsement of our recommendations by the WFSA
- 42
43 • Descriptions and links to our recommendations from the WFSA website
- 44
45 • Peer-reviewed manuscripts describing our methodology and our recommendations
- 46
47 • Presentations at influential national and international conferences, including the American
48 Society of Anesthesiologists, Anesthesia Patient Safety Foundation, and World Congress
49 of Anesthesiologists
- 50
51 • Presentations at hospital grand rounds in the US and globally
- 52
53
54
55
56
57
58
59
60

- Outreach to professional societies not only in high income countries, but also in middle and low income countries, to encourage use of the recommendations. This will include a description of the recommendations in their native language

Part 5: Evaluation of Initial Adoption using Semi-structure Interviews

Approximately twelve months after we disseminate the recommendations, we will conduct one-on-one semi-structured interviews with each participant to evaluate the initial adoption and implementation of the recommendations in each of the country income groups. The semi-structured interviews will be audio recorded and conducted either in-person or by telephone/video conference.

The semi-structured interview instrument shown in Figure 1 will be pilot tested and iteratively revised with our project steering committee members. It is based on the extensively studied RE-AIM framework,^{19,21,22} and includes: Introductory comments, questions with generic probes, questions with specific probes, final/summary questions, and closing statements.

Data Analysis:

Grounded Theory Analysis: In order to achieve thematic saturation (the point at which no new themes emerge from the interview data), we will interview at least 80 participants, n=20 from each of the four country income groups. We will follow the grounded theory approach to interpret qualitative data.³⁷⁻⁴⁰ Audio recordings of semi-structured interviews will be transcribed verbatim, reviewed/corrected for transcription accuracy and removal/masking of identifying information, and entered into ATLAS.ti software (Scientific Software Development, Berlin) for coding and analysis. Our study team will regularly review themes and emergent findings with the project steering committee. We will repeatedly look at alternative explanations for

1
2
3 interpretations of data, and rule them out or modify our initial interpretations. We will code data
4 into categories based on emergent themes. This iterative, analytic and reflective process will be
5 conducted as interview transcripts become available, allowing for modification of the coding
6 scheme as well as assuring that thematic saturation is reached.
7
8
9
10

11 12 13 **Patient and Public Involvement:**

14 Patients and the public were incorporated into our study design in several ways. First,
15 recommendations for perioperative medication safety that are in the public domain were
16 included as candidate recommendation for this study. Second, we incorporated national
17 professional societies (for anesthesiologists, surgeons, nurses, nurse anesthetists and
18 pharmacists) from around the world into our recruitment strategy, as described in the Study
19 Population and Recruitment section. Third, by making our recommendations publicly available,
20 we will involve patients and the public in the diffusion and dissemination of our
21 recommendations.
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **ETHICS AND DISSEMINATION**

36 This study was approved by the Human Research Committee/Institutional Review Board at
37 Partners Healthcare (2019P003567), and is registered on clinicaltrials.gov (NCT04240301). The
38 study will be overseen by a multidisciplinary, international steering committee, including
39 members from North America, Latin America, Europe, New Zealand, Asia and Africa.
40
41
42
43
44
45
46

47 This project will create and disseminate the first consensus-based recommendations for
48 perioperative medication safety that are tailored to country income level, using the World Bank's
49 four country income groups: high (includes the US), upper-middle, lower-middle and low
50 income.^{12,16} The project will include the entire medication use process (ordering, dispensing,
51 preparing, administering, documenting and monitoring) in preoperative holding areas, operating
52
53
54
55
56
57
58
59
60

rooms and post-anesthesia recovery areas. The resulting recommendations will make surgery safer for patients not only in high income countries but also in upper-middle, lower-middle and low income countries around the world.

By creating the first set of recommendations that are specifically tailored to a country's income and resource level, we will facilitate the successful dissemination and diffusion of our recommendations. Greenhalgh and colleagues performed an extensive literature review on adoption of innovation in health care³⁶ and found that diffusion and dissemination programs have been most effective when they:

1. Incorporate potential adopters' needs and perspectives, with particular attention to the cost-benefit tradeoff. We will achieve this in Part 2 via the Delphi Method, which will incorporate the perspectives and recommendations of all participants, with equal representation from high, upper-middle, lower-middle and low income countries.
2. Tailor different strategies to different demographic, structural and cultural groups, which we will achieve in Part 3: Prioritize the recommendations by their level of clinical importance for implementation in high, upper-middle, lower-middle and low income countries.
3. Use appropriate communication style and channels, which we will achieve via i) diffusion that is facilitated by our large, international group of participants, and ii) dissemination that is facilitated by the participation of and endorsement by the WFSA.³⁶

1
2
3 These strategies will ensure widespread diffusion and dissemination of our recommendations,
4 and thereby change the culture of medication safety, which currently leaves low resource
5 countries behind. Our inclusion of targeted recommendations for these areas will provide a
6 valuable resource for policy-makers, hospital administrators and frontline healthcare providers
7 to reduce the incidence of medication errors and their associated patient harm. Also, our
8 prioritization of the recommendations will allow easy identification of the most important
9 recommendations for future evaluation by randomized controlled trial. Finally, adoption of the
10 recommendations will make surgery and anesthesia safer both in the US and around the world.
11
12
13
14
15
16
17
18
19
20
21

22 The recommendations generated by this project will be shared globally via publication in peer-
23 reviewed journals, and descriptions and links on the websites of the World Federation of
24 Societies of Anesthesiologists and other professional organizations. Our findings will also be
25 presented at national and international meetings, and we will use grass-roots diffusion methods
26 via our large, international group of participants.
27
28
29
30
31
32
33
34

35 This project is important because it will make surgery safer for patients globally by creating and
36 disseminating the first consensus-based recommendations for perioperative medication safety
37 that are tailored to country income level. Widespread diffusion and dissemination of the resulting
38 recommendations has the potential to change the culture of medication safety, which currently
39 leaves low resource areas behind. Our inclusion of targeted recommendations for these areas
40 will provide a valuable resource for policy-makers, hospital administrators and frontline
41 healthcare providers to reduce the incidence of medication errors and their associated patient
42 harm.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Merry AF, Webster CS, Hannam J, et al. Multimodal system designed to reduce errors in recording and administration of drugs in anaesthesia: prospective randomised clinical evaluation. *BMJ*. 2011;343:d5543.
2. Nanji KC, Patel A, Shaikh S, Seger DL, Bates DW. Evaluation of perioperative medication errors and adverse drug events. *Anesthesiology*. 2016;124(1):25-34.
3. Fasting S, Gisvold SE. Adverse drug errors in anesthesia, and the impact of coloured syringe labels. *Canadian Journal of Anaesthesia*. 2000;47(11):1060.
4. Cooper JB, Newbower RS, Kitz RJ. An analysis of major errors and equipment failures in anesthesia management: Considerations for prevention and detection. *Anesthesiology*. 1984;60(1):34-42.
5. Neily J, Silla ES, Sum-Ping SJT, et al. Anesthesia Adverse Events Voluntarily Reported in the Veterans Health Administration and Lessons Learned. *Anesth Analg*. 2018;126(2):471-477.
6. Kurth CD, Tyler D, Heitmiller E, Tosone SR, Martin L, Deshpande JK. National pediatric anesthesia safety quality improvement program in the United States. *Anesth Analg*. 2014;119(1):112-121.
7. Anesthesiology Facts. 2019; <https://www.wfsahq.org/anaesthesiology-facts>, 2019.
8. Eichhorn J. APSF Hosts Medication Safety Conference. *Anesthesia Patient Safety Foundation Newsletter*. 2010;25(1):1-20.
9. Wahr JA, Abernathy J, Lazarra E, et al. Medication safety in the operating room: Literature and expert-based recommendations. *British Journal of Anaesthesia*. 2016;118(1):32-43.
10. Whitaker D, Brattebo G, Trenkler S, et al. The European Board of Anaesthesiology recommendations for safe medication practice: First update. *European Journal of Anaesthesiology*. 2017;34(1):4-7.
11. Guidelines for the Safe Management and Use of Medications in Anaesthesia. *Australian and New Zealand College of Anaesthetists*. 2017.
12. World Bank Country and Lending Groups. 2019; <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>. Accessed Sept 24, 2019.
13. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR. *The RAND/UCLA appropriateness method user's manual*. RAND Corporation;2001.
14. Hinkelbein J, Lamperti M, Akeson J, et al. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. *European Journal of Anaesthesiology*. 2018;35(1):6-24.
15. Mangione-Smith R, DeCristofaro AH, Setodji CM, et al. The quality of ambulatory care delivered to children in the United States. *New England Journal of Medicine*. 2007;357(15):1515-1523.
16. SooHoo NF, Lieberman JR, Farnig E, Park S, Jain S, Ko CY. Development of quality of care indicators for patients undergoing total hip or total knee replacement. *BMJ Quality and Safety*. 2011;20(2):153-157.
17. World Federation of Societies of Anesthesiologists. Member Societies. *World Federation of Societies of Anesthesiologists*. 2019; <https://www.wfsahq.org/about-us/member-societies>.
18. World Health Organization. *WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings*. World Health Organization; 2016.

19. Glasgow RE, Harden SM, Gaglio B, et al. RE-AIM planning and evaluation framework: Adapting to new science and practice with a 20-year review. *Front Public Health*. 2019;7:64.
20. Hayes C, O'Shea M, Foley-Nolan C, McCarthy M, Harrington J. Barriers and facilitators to adoption, implementation and sustainment of obesity prevention interventions in schoolchildren—a DEDIPAC case study. *BMC Public Health*. 2019;19(1):198.
21. RE-AIM. RE-AIM: Reach, Effectiveness, Adoption, Implementation, Maintenance. *RE-AIM*. 2019; <http://www.re-aim.org/>.
22. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: The RE-AIM framework. *American Journal of Public Health*. 1999;89(9):1322-1327.
23. Pagel C, Brown KL, McLeod I, et al. Selection by a panel of clinicians and family representatives of important early morbidities associated with paediatric cardiac surgery suitable for routine monitoring using the nominal group technique and a robust voting process. *BMJ open*. 2017;7(5):e014743.
24. Utey M, Gallivan S, Mills M, Mason M, Hargraves C. A consensus process for identifying a prioritised list of study questions. *Health Care Management Science*. 2007;10(1):105-110.
25. Young HP. Condorcet's theory of voting. *American Political Science Review*. 1988;82(4):1231-1244.
26. Gehrlein WV. Condorcet's paradox. *Theory and Decision*. 1983;15(2):161-197.
27. Borg I, Groenen PJ, Mair P. *Applied multidimensional scaling*. Springer Science and Business Media; 2012.
28. Hout MC, Papesh MH, Goldinger SD. Multidimensional scaling. *Wiley Interdisciplinary Reviews: Cognitive Science*. 2013;4(1):93-103.
29. Mugavin ME. Multidimensional scaling: A brief overview. *Nursing Research*. 2008;57(1):64-68.
30. Mair P, Borg I, Rusch T. Goodness-of-fit assessment in multidimensional scaling and unfolding. *Multivariate Behavioral Research*. 2016;51(6):772-789.
31. Garson GD. *Cluster Analysis*. Asheboro, NC, USA: Statistical Publishing Associates; 2014.
32. Mirkin B. Clustering: A data recovery approach. Vol 19: Chapman and Hall/CRC, Boca Raton, FL, USA; 2012.
33. Hanke K, Liu JH, Sibley CG, et al. "Heroes" and "villains" of world history across cultures. *PLoS One*. 2015;10(2):e0115641.
34. Beurskens AJ, Swinkels RA, Pool JJ, Batterham RW, Osborne RH, de Vet HC. The burden of neck pain: Its meaning for persons with neck pain and healthcare providers, explored by concept mapping. *Quality of Life Research*. 2016;25(5):1219-1225.
35. Nowicki EA, Brown JD, Dare L. Educators' evaluations of children's ideas on the social exclusion of classmates with intellectual and learning disabilities. *Journal of Applied Research in Intellectual Disabilities*. 2018;31(1):e154-e163.
36. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: Systematic review and recommendations. *Milbank Q*. 2004;82(4):581-629.
37. Nanji KC, Rothschild JM, Boehne JJ, Keohane CA, Ash JS, Poon EG. Unrealized potential and residual consequences of electronic prescribing on pharmacy workflow in the outpatient pharmacy. *Journal of the American Medical Informatics Association*. 2014;21(3):481-486.
38. Ash JS, Sittig DF, Dykstra R, Campbell E, Guappone K. The unintended consequences of computerized provider order entry: Findings from a mixed methods exploration. *International journal of medical informatics*. 2009;78(Suppl 1):S69-76.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
39. Glaser B, Strauss A. *The discovery of grounded theory: Strategies for qualitative research*. Chicago, IL, USA: Aldine; 1967.
40. Miles MB, Huberman AM. *Qualitative data analysis: An expanded sourcebook*. 2 ed. Thousand Oaks, CA, USA: Sage Publications; 1994.

For peer review only

AUTHOR CONTRIBUTIONS

Author KCN contributed to study design, statistical plan, drafting and revising the manuscript.

Author AFM contributed to study design, statistical plan, and revising the manuscript. Author SS contributed to drafting and revising the manuscript. Author CP contributed to study design, statistical plan, and revising the manuscript. Author HD contributed to the statistical plan and revising the manuscript. Author JW contributed to study design, statistical plan, and revising the manuscript. Author AG contributed to study design, statistical plan, and revising the manuscript. Author BAO contributed to study design, statistical plan, and revising the manuscript.

COMPETING INTERESTS

Dr. Nanji receives author royalties from UpToDate, Inc (Waltham MA). Dr. Merry has shares in Safersleep LLC (Auckland NZ) and chairs its Board. Dr. Wahr received speaker honoraria from the Anesthesia Patient Safety Foundation (Rochester MN) and the Aspen Institute (Aspen CO). Dr. Gelb receives consulting fees from Masimo Inc (Irvine CA) and Haisco Pharmaceutical (Shannan, China). He is also Secretary of the World Federation of Societies of Anesthesiologists (London UK). Dr. Orser serves on the Board of Directors of the Institute for Safe Medication Practices (ISMP) Canada (Toronto Canada). The remaining authors have no competing interests.

FUNDING STATEMENT

This work was supported by a grant from the Agency for Healthcare Research and Quality (AHRQ, Rockville, MD, #1K08HS024764-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ. The did not AHRQ have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

FIGURE LEGENDS

Figure 1. Preliminary Interview Instrument.

This will serve as the basis for the final semi-structured interview instrument to be used in Part 5: Evaluation of Initial Adoption using Semi-structure Interviews. The preliminary instrument will be pilot tested and iteratively revised with our project steering committee, to arrive at the final interview instrument.

For peer review only

FIGURE 1: PRELIMINARY INTERVIEW INSTRUMENT

Introductory comments: We will thank participants, obtain verbal informed consent for the interview and audio recording, explain that the interview is confidential, obtain demographic information, and begin audio recording.

Questions with generic probes: We will start with a general open-ended question, “Please tell me how the recommendations were implemented.” To help elicit information, we will use additional probes such as “Please tell me more about...”, “Help me understand...”, and “Other participants have said XXX. What do you think?”

Questions with specific probes:

Reach: a) How many of your colleagues would you estimate are aware of the recommendations (none, a few, half, most, all)? b) How has communication and collaboration related to medication safety changed from pre-recommendations to the present?

Efficacy: a) How effective are the recommendations (What were the problems and how did you overcome them?) b) Were any unintended consequences related to patient safety or workflow noted? c) Were there any secondary benefits (e.g., enhanced safety awareness)? d) Does your hospital maintain an incident reporting system? If yes, have you noticed a change in the number, type or severity of medication-related incidents reported? e) Does your country maintain a national incident reporting system? If yes, have you noticed a change in the number, type or severity of medication-related incidents reported?

Adoption: a) Where is your center in the implementation process of the recommendations (not started, early stages, middle, almost complete, complete)? b) What about other centers in your area (not started, early stages, middle, almost complete, complete)?

Implementation: a) What barriers to implementation were identified and how were they addressed? b) What enabling factors were identified and how were they used? (e.g., human “champions”, pre-existing robust QI programs) c) Were any workarounds developed to avoid a recommendation? What were they? What issues prompted providers to resort to a workaround? d) What resources were used to support implementation (existing structure such as a QI team, or a new structure such as a new implementation committee)? e) What surprised you because it went so smoothly? f) Did implementation take longer than you thought?

Maintenance: a) How did the recommendations integrate within pre-implementation workflows (seamless, minor “add on,” or required major changes)? b) What resistance have you encountered (e.g., naysayers, lack of resources, etc)?

Final questions: a) What haven’t I asked that will be helpful for us to know? b) Do you have any other comments about what we have discussed today?

Closing statements: Thank you, re-iterate that the interview is confidential, provide our email and telephone numbers in case the participant would like to contact us to add information.